Related Experiment Video
Updated: Jul 3, 2025

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
Published on: December 5, 2016
RNA N6-methyladenosine modifications in urological cancers: from mechanism to application
Lei Yang1, Jianming Ying2, Qian Tao3
1Department of Urology, Peking University First Hospital, Institute of Urology, National Research Center for Genitourinary Oncology, Peking University, Beijing, China.
Abstract:
The N6-methyladenosine (m6A) modification is the most common modification of messenger RNAs in eukaryotes and has crucial roles in multiple cancers, including in urological malignancies such as renal cell carcinoma, bladder cancer and prostate cancer. The m6A RNA modification is controlled by three types of regulators, including methyltransferases (writers), demethylases (erasers) and RNA-binding proteins (readers), which are responsible for gene regulation at the post-transcriptional level. This Review summarizes the current evidence indicating that aberrant or dysregulated m6A modification is associated with urological cancer development, progression and prognosis. The complex and context-dependent effects of dysregulated m6A modifications in urological cancers are described, along with the potential for aberrantly expressed m6A regulators to provide valuable diagnostic and prognostic biomarkers as well as new therapeutic targets.
Insights
N6-methyladenosine (m6A) RNA modification is crucial in urological cancers. Dysregulated m6A regulators show potential as diagnostic biomarkers and therapeutic targets for kidney, bladder, and prostate cancers.
Area of Science:
- Molecular Biology
- Oncology
- Epigenetics
Background:
- N6-methyladenosine (m6A) is the most prevalent mRNA modification in eukaryotes.
- m6A plays critical roles in various cancers, including urological malignancies like renal cell carcinoma, bladder cancer, and prostate cancer.
- m6A modification is regulated by writers, erasers, and readers, influencing post-transcriptional gene expression.
Purpose of the Study:
- To review the current evidence on the association between m6A modification and urological cancers.
- To describe the complex and context-dependent roles of dysregulated m6A modifications in these cancers.
- To highlight the potential of m6A regulators as diagnostic/prognostic biomarkers and therapeutic targets.
Main Methods:
- Literature review of studies investigating m6A modification in urological cancers.
- Analysis of evidence linking m6A regulators to cancer development, progression, and prognosis.
- Synthesis of information on the functional impact of m6A dysregulation.
Main Results:
- Aberrant m6A modification is significantly associated with the development, progression, and prognosis of urological cancers.
- Dysregulated m6A regulators exhibit complex, context-dependent effects in these malignancies.
- Evidence suggests m6A regulators can serve as valuable biomarkers and therapeutic targets.
Conclusions:
- m6A modification is a key player in urological cancer biology.
- Targeting m6A regulators offers promising avenues for diagnostics and therapeutics in urological cancers.
- Further research into m6A pathways is warranted for clinical applications.
Related Concept Videos
RNA Editing
RNA Stability
Transfer RNA Synthesis
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
Epigenetic Regulation
X-chromosome...
Nuclear Export of mRNA
MicroRNAs

